BRIEF published on 03/23/2026 at 07:35, 7 months 10 days ago Sensorion Updates on Audiogene Trial and Advances GJB2-GT Clinical Trials Gene Therapy Sensorion Hearing Loss SENS-601
BRIEF published on 03/18/2026 at 07:35, 7 months 15 days ago Sensorion Reports 2025 Results and Corporate Updates Financial Results Gene Therapy Sensorion Hearing Loss Sanofi Investment
PRESS RELEASE published on 03/18/2026 at 07:30, 7 months 15 days ago Inside Information / News release on accounts, results Sensorion reports full-year 2025 results, provides corporate update, and announces release of annual report. Key milestones in gene therapies for hearing loss. Financial highlights and future expectations highlighted Financial Highlights Full-year Results Sensorion Gene Therapies Future Milestones
BRIEF published on 02/17/2026 at 07:35, 8 months 13 days ago Leadership Transition at Sensorion amid Strategic Focus on Hearing Loss Therapies Biotechnology Gene Therapy Leadership Change Sensorion Hearing Loss
BRIEF published on 02/17/2026 at 07:35, 8 months 13 days ago Sensorion announces changes in its management Change Of Direction Sensory Auditory Therapy Sanofi Financing Medical Pipeline
PRESS RELEASE published on 02/17/2026 at 07:30, 8 months 13 days ago Inside Information / Other news releases Sensorion announces Nawal Ouzren stepping down as CEO for personal reasons. Amit Munshi to serve as Interim CEO. Sanofi-led financing for pipeline assets Leadership Changes Sanofi Sensorion Amit Munshi Nawal Ouzren
BRIEF published on 02/06/2026 at 07:35, 8 months 24 days ago Sensorion to Participate in ARO 49th Annual Midwinter Meeting Biotechnology Gene Therapy Sensorion Hearing Loss ARO Meeting
PRESS RELEASE published on 02/06/2026 at 07:30, 8 months 24 days ago Inside Information / Other news releases Sensorion to present SENS-601 gene therapy at ARO 49th Annual Midwinter Meeting in Puerto Rico Gene Therapy Sensorion Hearing Loss SENS-601 ARO 49th Annual Midwinter Meeting
BRIEF published on 01/28/2026 at 07:48, 9 months 5 days ago Sensorion Secures €60 Million Financing to Advance Hearing Loss Therapies Gene Therapy Biotech Financing Sensorion Hearing Loss Sanofi Investment
PRESS RELEASE published on 01/28/2026 at 07:43, 9 months 5 days ago Inside Information / Other news releases Sensorion announces €60 million financing with a €20M strategic investment from Sanofi and support from global healthcare specialists to advance genetic medicine pipeline. Cash runway extended until H1 2027 Financing Sanofi Sensorion Genetic Medicine Healthcare Specialists
Published on 11/02/2026 at 15:00, 1 hour 17 minutes ago CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 2 hours 17 minutes ago GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Published on 11/02/2026 at 14:00, 2 hours 17 minutes ago Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
Published on 11/02/2026 at 13:30, 2 hours 47 minutes ago Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
Published on 11/02/2026 at 13:30, 2 hours 47 minutes ago Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
Published on 11/02/2026 at 15:58, 19 minutes ago Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 15:19, 58 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/02/2026 at 15:25, 52 minutes ago Guillemot Corporation S.A. | Information regarding the total number of voting rights and shares 31/10/2026
Published on 10/30/2026 at 23:00, 2 days 17 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 22 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 3 days 4 hours ago Capital increase through exercise of subscription rights
